In a nutshell The aim of this study was to evaluate the safety of giving stereotactic radiosurgery (SRS) at the same time as other cancer treatments for patients who have brain metastasis. The study found that SRS given in combination with chemotherapy, immunotherapy, or targeted therapy was safe with low levels of side effects. Some background The...
Read More
In a nutshell This trial is aiming to examine the safety and effectiveness of experimental treatment DF6002 alone or in combination with nivolumab (Opdivo) in the treatment of advanced solid tumors, including lung cancer. The main outcomes to be measured are drug toxicity and the response rate of patients to the drug. This trial is being carried out in...
Read More
In a nutshell This trial compared the use of standard paclitaxel (SP; Taxol) versus a new nanoparticle micellar preparation of paclitaxel (NmP) as a first-line treatment for non-small cell lung cancer (NSCLC). The authors found that NmP had better effectiveness and safety in treating NSCLC than SP. Some...
Read More
In a nutshell This trial was carried to look at the use of erlotinib (Tarceva) with radiotherapy (RT) compared to standard treatment for EGFR-positive non-small cell lung cancer (NSCLC) that cannot be removed surgically. The authors found that erlotinib and RT improved survival without cancer worsening in these patients. Some...
Read More
In a nutshell This study compared 1-year fixed-duration versus continuous nivolumab (Opdivo) for the treatment of previously treated advanced non-small-cell lung cancer (NSCLC). The authors found that continuing nivolumab beyond a fixed duration of 1-year may improve patient outcomes. Some background NSCLC is the most common form of lung cancer....
Read More
In a nutshell This study evaluated the risk of heart-related (HR) side effects in patients with lung cancer treated with immune checkpoint inhibitors (ICI). Patients with lung cancer were shown to have a higher risk of developing HR side effects when treated with ICIs. Some background ICIs are a type of cancer therapy used to treat a wide variety of...
Read More
In a nutshell The study evaluated the timing of radiotherapy (RT) and immune-checkpoint therapy (ICT) on the outcomes of patients with brain metastasis (BrM) resulting from melanoma and non-small cell lung cancer (NSCLC). The authors found that RT and ICT given at the same time may improve response and delay recurrence in these patients. Some background...
Read More
In a nutshell This study looked at the effectiveness and safety of belotecan (Bel; Camtobell) and topotecan (Top; Hycamtin) as therapy for sensitive relapsed small-cell lung cancer (SCLC). The authors found that Bel could be used as an alternative to Top for sensitive-relapsed SCLC. Some background SCLC...
Read More
In a nutshell This study was carried out to look at the use of a reduced dose of erlotinib (Tarceva) in the treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC). The authors found that lower-dose erlotinib was as effective as standard dose gefitinib (Iressa) in these patients. Some background NSCLC is the...
Read More
In a nutshell This study was carried out to compare the effectiveness of chemoimmunotherapy (CIT) to immunotherapy (IT) alone for advanced non-small cell lung cancer (NSCLC). The authors found that there was no significant benefit in overall survival with CIT over IT. Some background NSCLC is the most common form of lung cancer. NSCLC is responsible...
Read More
In a nutshell The study compared outcomes of lorlatinib (Lorbrena) with crizotinib (Xalkori) in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) with ALK mutations (genetic abnormalities). The main finding was that patients receiving lorlatinib had longer progression-free survival (PFS) and a higher response in the...
Read More
In a nutshell This trial is evaluating the safety and effectiveness of experimental treatment REGN5093 in patients with advanced non-small-cell lung cancer (NSCLC). The main outcomes to be evaluated will be the number of patients who experience side effects, the maximum dose without significant side effects, and response to treatment. This trial is...
Read More
